Imeik was incorporated in Beijing, China.
We independently developed China's first dermal filler product EME®, establishing an industry milestone for regulated Class III medical aesthetic products in the Chinese market.
Acquired 25.4% equity in Huons BioPharma (South Korea), consolidating the exclusive distribution rights for Hutox® botulinum toxin type A in China.
Our in-house developed product Hearty® – the world's first dermal filler specifically approved for neck wrinkle rejuvenation – debuted commercially. It rapidly dominated the market and remains China's top-selling medical aesthetic product, with cumulative sales exceeding 20 million units by 2024.
Within just 14 years, Imeik became China's leading domestic manufacturer by market share in HA-based dermal fillers. We achieved full-scale production capabilities for all Class III medical devices while initiating global expansion.
Our proprietary facial implant thread product Tightly® premiered as China's first in-house developed thread lifting solution, filling a critical market gap.
Imeik was listed on the Shenzhen Stock Exchange (stock code 300896), and since then, it has firmly established itself as a leading company in China's medical aesthetics market.
We launched CureWhite® as the world's pioneering and only approved dermal filler containing PLLA-PEG microspheres. This innovative product has achieved a historical breakthrough, demonstrating Imeik's R&D leadership in the medical aesthetics sector.
With 11 Class III medical device products on the market, Imeik secured the No.1 market position in China's dermal filler segment among all brands, establishing a robust foundation for global medical aesthetics operations.
Imeik executed China's largest-ever medical aesthetics acquisition by purchasing an 85% stake in South Korea's REGEN Biotech. This landmark deal positioned us as the only company with multiple types of regenerative injectable products, consolidating our leadership in regenerative aesthetics while advancing global strategic initiatives.